June
2004 | Vol. 1, No. 1
1 AMA PRA Category 1 Credit
Table of Contents
Recent Data With the Humanized Anti–Vascular Endothelial Growth Factor Antibody Bevacizumab in Colorectal Cancer
Fairooz F. Kabbinavar, MD
Overview of Strategies to Inhibit the Vascular Endothelial Growth Factor Pathway in Oncology
Curtis J. Wray, MD
Syed A. Ahmad, MD
The Emerging Role of Anti–Vascular Endothelial Growth Factor Therapy in Resectable Pancreatic Cancer
Christopher H. Crane, MD
Learning Objectives | Back to top
Upon completion of this learning material, physicians should be able to:
- Evaluate the safety of an antiangiogenic monoclonal antibody in patients with metastatic colorectal cancer
- Describe the role of the VEGF pathway in the development of
colorectal cancer
- Discuss the clinical trials that are evaluating the use of an
antiangiogenic monoclonal antibody in pancreatic cancer
Activity Goals | Back to top
Tumor growth and metastasis is highly dependent on the ability of the tumor to promote the development of its own blood supply. Vascular endothelial growth factor (VEGF) is a critical induction signal for angiogenesis in the embryo and in tumors; however, the survival of endothelial cells in mature vasculature is not VEGF dependent. Thus, VEGF represents an attractive molecular target for cancer therapy because disruption of VEGF signaling might prevent tumor-stimulated neovascularization without compromising the function of the existing vasculature. Anti-VEGF antibodies are currently approved for use in combination with chemotherapy in colorectal cancer, but antiangiogenic strategies might synergize with standard chemotherapy regimens and produce improved outcomes for patients with other tumor types.
The purpose of this activity is to update physicians on
advances with VEGF- and VEGF receptor-targeted agents.
Target Audience | Back to top
This publication is intended for medical oncologists involved in the care of patients with solid tumors. No specific skills or knowledge other than a basic training in oncology are required for successful participation in this activity.
Accreditation | Back to top
Physicians' Education Resource is accredited by the Accreditation Council for
Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource designates this educational activity for a
maximum of 1 category 1 credit toward the AMA Physician's Recognition Award.
Each physician should claim only those credits that he/she actually spent in
the activity.
Release date: June 30, 2004 Expiration date: June 30, 2005
Disclosure Policy | Back to top
As a sponsor accredited by the Accreditation Council for Continuing Medical Education,
Physicians' Education Resource must ensure balance, independence, objectivity
and scientific rigor in all its sponsored activities. All faculty participating
in a sponsored activity are expected to disclose to the activity audience any
significant financial interest or other relationship (1) with the manufacturer(s)
of any commercial product(s) and (2) with any commercial supporters of the activity.
(Significant financial interest or other relationships can include such things
as grants or research support, employee, consultant, major stockholder, member
of speaker's bureau, etc.) The intent of this disclosure is not to prevent
an author with a significant financial or other relationship from publishing
an article, but rather to provide readers with information on which they can
make their own judgements. It remains for the readers to determine whether the
author's interests or relationships may influence the publication with
regard to exposition or conclusion.
Fairooz F. Kabbinavar, MD
Speaker's Bureau – Genentech BioOncology
Curtis J. Wray, MD
Has nothing to disclose
Syed A. Ahmad, MD
Has nothing to disclose
Christopher H. Crane, MD
Grant or Research Support – Genentech BioOncology
Paid Consultant – Roche Pharmaceuticals
Speaker's Bureau – Roche Pharmaceuticals
The articles in this CME activity might include discussion of investigational and/or unlabeled uses of drugs. If an article includes discussion of investigational and/or unlabeled uses of a drug, specific information islocated before the article. Please refer to the full prescribing information for each drug discussed in this newsletter for FDA-approved dosing, indications, and warnings
Vascular Endothelial Growth Factor in Oncology is
produced by Physicians' Education Resource, Dallas, TX. An unrestricted educational
grant
for this publication was provided by Genentech BioOncology.
The views and opinions expressed in this publication are those of the authors
and do not necessarily reflect the views of the sponsor or publisher. Although
great care has been taken in compiling and checking the information given in
this publication to ensure accuracy, the authors, Genentech
BioOncology, and Physicians' Education Resource and its servants
or agents shall not be responsible or in any way liable for the continued currency
of the information or for any errors, omissions, or inaccuracies in this publication,
whether arising from negligence or otherwise howsoever or for any consequences
arising therefrom.
Please consult full prescribing information for any drugs or procedures discussed within.
All rights reserved. No part of this publication may be translated, reproduced, stored, or transmitted by any means or in any type of media form including electronic, mechanical photocopying, recording, broadcasting, or otherwise without prior permission from the publisher.
©Copyright 2004 by Physicians' Education
Resource. No material may be reproduced in whole or in part, in any form, without
written permission from the publisher.
All correspondence should be directed to: Editor, Vascular Endothelial Growth Factor in Oncology
Physicians' Education Resource
3535 Worth St.
Suite 4802
Dallas, TX 75246
Phone: (214) 820-8079
Fax: (214) 820-8844
E-mail:CME@pergrouplp.com
Editorial Staff:
Publishing Manager – B. Diane Gambill, PhD
Assistant Publishing Manager – David Lee, PhD
Managing Editor – Jennifer Klem, PhD
Senior Medical Editor – Jay Delmar, PhD
Associate Medical Editor – Jill Cowherd
Medical Editor/Proofreader – Pete Sloan
Acquisitions – Anissa Mitchell
Design & Production:
Art Director – Todd J. Hagler
Senior Graphic Artist – Kelly D. Martin
Graphic Artist – Kevin Graves
Web Developer – Jason Salamone
Back to top
|
